OTHER INFECTIOUS DISEASES — Sales to customers (Note 9)
Johnson & Johnson OTHER INFECTIOUS DISEASES — Sales to customers (Note 9) decreased by 7.5% to $37.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 9.8%, from $41.00M to $37.00M. Over 4 years (FY 2021 to FY 2025), OTHER INFECTIOUS DISEASES — Sales to customers (Note 9) shows a downward trend with a -16.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful commercialization or market penetration of the infectious disease product portfolio, while a decrease may signal patent expirations, increased competition, or declining demand for these specific therapies.
Detailed definition
This metric represents the total net revenue generated from the sale of pharmaceutical products specifically categorized...
Peer comparison
Peers typically report this as revenue from specialized infectious disease or anti-infective product lines, often categorized within their broader pharmaceutical or specialty medicine segments.
jnj_segment_other_infectious_diseases_sales_to_customers_note_9Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $88.00M | $99.00M | $68.00M | $91.00M | $83.00M | $77.00M | $67.00M | $82.00M | $79.00M | $74.00M | $1.18B | $78.00M | $233.00M | $56.00M | $45.00M | $41.00M | $47.00M | $47.00M | $40.00M | $37.00M |
| QoQ Change | — | +12.5% | -31.3% | +33.8% | -8.8% | -7.2% | -13.0% | +22.4% | -3.7% | -6.3% | >999% | -93.4% | +198.7% | -76.0% | -19.6% | -8.9% | +14.6% | +0.0% | -14.9% | -7.5% |
| YoY Change | — | — | — | — | -5.7% | -22.2% | -1.5% | -9.9% | -4.8% | -3.9% | >999% | -4.9% | +194.9% | -24.3% | -96.2% | -47.4% | -79.8% | -16.1% | -11.1% | -9.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's other infectious diseases — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported other infectious diseases — sales to customers (note 9) of $37.00M in Q1 2026.
- How has Johnson & Johnson's other infectious diseases — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's other infectious diseases — sales to customers (note 9) decreased by 9.8% year-over-year, from $41.00M to $37.00M.
- What is the long-term trend for Johnson & Johnson's other infectious diseases — sales to customers (note 9)?
- Over 4 years (2021 to 2025), Johnson & Johnson's other infectious diseases — sales to customers (note 9) has grown at a -16.7% compound annual growth rate (CAGR), from $363.00M to $175.00M.
- What does other infectious diseases — sales to customers (note 9) mean?
- Total revenue earned from the sale of products in the Other Infectious Diseases therapeutic category.